0.8066

5.07% -0.0431

After Hours: .86 0.0534 +6.62%

Prokidney Corp (PROK)

Overview News Price History Option Chain Financials Discussions Forecast

Prokidney Corp stock is traded at $0.8066, with a volume of 590.08K. It is down -5.07% in the last 24 hours and up +1.34% over the past month. ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Previous Close:

$0.8497

Open:

$0.85

24h Volume:

590.08K

Relative Volume:

0.76

Market Cap:

$104.49M

Revenue:

Net Income/Loss:

$-35.47M

P/E Ratio:

-1.4151

EPS:

-0.57

Net Cash Flow:

$-124.27M

1W Performance:

+11.81%

1M Performance:

+1.34%

6M Performance:

-52.41%

1Y Performance:

-78.72%

1-Day Range:

$0.772

$0.8999

1-Week Range:

$0.71

$0.8999

52-Week Range:

$0.4603

$4.44

Prokidney Corp Stock (PROK) Company Profile

Name

Prokidney Corp

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

336-999-7028

Address

2000 FRONTIS PLAZA BLVD., WINSTON-SALEM

Employee

204

Twitter

Next Earnings Date

2024-12-09

Latest SEC Filings

PROK's Discussions on Twitter

Compare PROK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PROK Prokidney Corp	0.8066	93.45M	0	-35.47M	-124.27M	-0.57
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Prokidney Corp Stock (PROK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-24	Initiated	JP Morgan	Neutral
Sep-10-24	Initiated	Guggenheim	Buy
Mar-07-24	Resumed	Morgan Stanley	Equal-Weight
Jan-02-24	Downgrade	BofA Securities	Buy → Neutral
Jul-25-23	Initiated	BTIG Research	Buy
Dec-21-22	Initiated	Jefferies	Buy
Nov-10-22	Initiated	Morgan Stanley	Equal-Weight
Oct-18-22	Initiated	UBS	Buy
Oct-14-22	Initiated	Citigroup	Buy
Sep-23-22	Initiated	BofA Securities	Buy
Sep-02-22	Initiated	Evercore ISI	Outperform

View All

Prokidney Corp Stock (PROK) Latest News

May 14, 2025

ProKidney quarterly loss grows as it nears two key milestones - Winston-Salem Journal

May 14, 2025

ProKidney Up 26%, Insiders Still In The Red By US$35m - simplywall.st

May 14, 2025

May 13, 2025

Wells Fargo & Company MN Purchases 18,431 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World

May 13, 2025

ProKidney Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times

May 12, 2025

ProKidney Corp. (NASDAQ:PROK) Shares Bought by Barclays PLC - Defense World

May 12, 2025

May 10, 2025

Mariner LLC Has $64,000 Stake in ProKidney Corp. (NASDAQ:PROK) - The AM Reporter

May 10, 2025

Mariner LLC Sells 15,937 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World

May 10, 2025

May 07, 2025

PROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and More - Nasdaq

May 07, 2025

ProKidney Corp. (NASDAQ:PROK) Shares Bought by Renaissance Technologies LLC - Defense World

May 07, 2025

May 06, 2025

JPMorgan Chase & Co. Buys 19,585 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World

May 06, 2025

May 02, 2025

ProKidney (PROK) Expected to Announce Quarterly Earnings on Friday - Defense World

May 02, 2025

May 01, 2025

The ProKidney Corp (PROK) had a good session last reading, didn’t it? - uspostnews.com

May 01, 2025

Apr 30, 2025